Showing results (51-60 of 90) with videos related to
Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 26, 2007
Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology GroupHossein Borghaei, R Katherine Alpaugh, Patricia Bernardo, et al.JAMA Oncology|March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized TrialNaomi B Haas, Judith Manola, Janice P Dutcher, et al.Cancer Medicine|August 18, 2021
Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trialCaitlin C Murphy, Hannah M Fullington, David E Gerber, et al.Cancer Investigation|March 20, 2003
A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893)Roland T Skeel, Jie Huang, Judith Manola, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimusJose Pablo Maroto, Gary Hudes, Janice P Dutcher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinomaBrian I Rini, George Wilding, Gary Hudes, et al.Targeted Oncology|September 25, 2015
Effect of Renal Impairment on the Pharmacokinetics and Safety of AxitinibYing Chen, Brian I Rini, Robert J Motzer, et al.Cancer|June 16, 2009
Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alphaRobert A Figlin, Paul de Souza, David McDermott, et al.Investigational New Drugs|January 4, 2020
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinomaAna M Molina, Johannes C van der Mijn, Paul Christos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.Pageof 9